Sidra Medicine first hospital in MENA to implant newly certified artificial heart valve


QF Entity participation in clinical trials leads to approval of the Venus P-Valve for worldwide use

08 November 2022, Doha, QatarSidra Medicine has been selected as the first hospital in the Middle East and North Africa region to offer the newly commercially certified Venus P-Valve for transcatheter pulmonary valve implantations. The artificial valve is a minimally invasive procedure used on patients with defective pulmonary valves.

Prof. Ziyad M. Hijazi, Chief Medical Officer at Sidra Medicine was the global principal investigator for a consortium of international cardiac interventionalists from Asia, Europe, Qatar and South America, participating in clinical trials to evaluate the Venus P-Valve. Qatar was one of the first countries in the world to conduct clinical trials in 2017, in a joint collaboration with Sidra Medicine and Hamad Medical Corporation.

Prof. Hijazi said: “This has been an exciting and collaborative journey of success of a new artificial valve that has moved from research and development to becoming a commercially certified product. Since attaining European CE certification, the valve has been assessed to meet safety, health and environmental protection requirements. This has expanded the range of minimally invasive valve implantation options for cardiac patients worldwide.”

Current artificial valves in the market only cater to 25-30 per cent of patients with defective pulmonary valves. The self-expanding Venus P-Valve, can be customized according to the shape of the patient’s heart – ensuring accuracy in positioning. This means that the other 70-75 per cent of patients, who were limited to having to undergo open heart surgery to replace their defective pulmonary valves, now have the Venus P-Valve as an officially certified alternative.

“I am proud of our Heart Center team at Sidra Medicine who have played a key role in endorsing the efficacy of the Venus P-Valve during the clinical trials, which has already benefitted 10 patients in Qatar. We hope to treat more children and adults requiring pulmonary valve implantations as we have successfully proven our expertise with this particular valve. We are already seeing interest from other hospitals and patients in the MENA region,” continued Prof. Hijazi.

Prof. Hijazi and Prof. Younes Boudjemline from the Heart Center, recently implanted the newly certified Venus P-valve on a patient in Qatar.

For more information:
The Heart Center:
International Patient Services: